Destiny Pharma plc – US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections

/in

Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, notes an increased focus on the importance of infection prevention by the Center for Disease Control (“CDC”), Food and Drug Administration (“FDA”), and the medical community in […]

Read more

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

/in

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors 25 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical […]

Read more

2022 Novo Holdings Seed Investments team Re-view/Business Update

/in

Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and MinervaX) Led three new seed investments and incubating additional projects Expanded team as part of strong investment in global talent to access innovation REPAIR Impact Fund making strides in the vital combat […]

Read more

Neuraxpharm completes its presence in the Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg

/in

Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients Brussels and Düsseldorf – January 24, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence […]

Read more

NeoPhore completes extension to Series B financing to further advance discovery pipeline

/in

Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension. The syndicate comprised its Series B subscribing investors including CRT Pioneer Fund, Claris Ventures, 2Invest, […]

Read more